Monopar Therapeutics Inc. Stock-Based Compensation
Monopar Therapeutics Inc. (MNPR) reported Stock-Based Compensation of $3.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.43M, a 11.64% increase year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.69M, a 24.94% increase year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.10M, a 296.29% increase year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.10M, a 452.03% increase year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $4.84M, a 324.08% increase from fiscal 2024.
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.14M, a 39.89% decline from fiscal 2023.
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.90M, a 15.63% increase from fiscal 2022.
- Monopar Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.64M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.12M 10-Q · filed 2026-08-12 | $4.23M derived: sum of 3 quarters · filed 2026-08-12 | $5.32M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $1.69M 10-Q · filed 2026-05-14 | $2.80M derived: sum of 2 quarters · filed 2026-05-14 | $3.90M derived: sum of 3 quarters · filed 2026-05-14 | $5.18M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.20M derived: sum of 2 quarters · filed 2026-03-27 | $3.48M derived: sum of 3 quarters · filed 2026-08-12 | $4.84M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.38M derived: sum of 2 quarters · filed 2026-08-12 | $3.73M 10-Q · filed 2025-11-13 | $4.01M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.63M 10-Q · filed 2026-08-12 | $2.91M derived: sum of 3 quarters · filed 2026-08-12 | $3.11M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $1.36M 10-Q · filed 2026-05-14 | $1.63M derived: sum of 2 quarters · filed 2026-05-14 | $1.83M derived: sum of 3 quarters · filed 2026-05-14 | $2.17M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $278.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $477.73K derived: sum of 2 quarters · filed 2026-03-27 | $812.12K derived: sum of 3 quarters · filed 2026-03-27 | $1.14M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $199.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $533.51K derived: sum of 2 quarters · filed 2025-11-13 | $862.17K 10-Q · filed 2025-11-13 | $1.34M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $334.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $663.05K 10-Q · filed 2025-08-12 | $1.14M derived: sum of 3 quarters · filed 2025-08-12 | $1.61M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $328.66K 10-Q · filed 2025-05-13 | $802.87K derived: sum of 2 quarters · filed 2025-05-13 | $1.28M derived: sum of 3 quarters · filed 2025-05-13 | $1.75M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $474.21K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $948.34K derived: sum of 2 quarters · filed 2025-03-31 | $1.42M derived: sum of 3 quarters · filed 2025-03-31 | $1.90M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $474.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $947.43K derived: sum of 2 quarters · filed 2024-11-08 | $1.42M 10-Q · filed 2024-11-08 | $1.82M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $473.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $949.50K 10-Q · filed 2024-08-09 | $1.34M derived: sum of 3 quarters · filed 2024-08-09 | $1.73M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | $476.21K 10-Q · filed 2024-05-09 | $869.63K derived: sum of 2 quarters · filed 2024-05-09 | $1.26M derived: sum of 3 quarters · filed 2024-05-09 | $1.62M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $393.42K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $784.16K derived: sum of 2 quarters · filed 2024-03-28 | $1.14M derived: sum of 3 quarters · filed 2024-03-28 | $1.64M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $390.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $748.03K derived: sum of 2 quarters · filed 2023-11-09 | $1.25M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $357.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $857.11K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $499.81K 10-Q · filed 2023-05-11 | ||||
| 2021-09-30 | $392.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $749.66K derived: sum of 2 quarters · filed 2022-11-10 | $1.12M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $357.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $725.83K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $368.23K 10-Q · filed 2022-05-12 | ||||
| 2020-09-30 | $283.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $532.60K derived: sum of 2 quarters · filed 2021-11-12 | $989.57K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $248.89K 10-Q · filed 2020-08-06 | $705.86K 10-Q · filed 2021-08-12 | $469.65K 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | $220.76K 10-Q · filed 2020-05-07 | ||||
| 2019-09-30 | $154.91K 10-Q · filed 2019-11-12 | $319.51K derived: sum of 2 quarters · filed 2020-08-06 | $470.23K 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $164.60K 10-Q · filed 2020-08-06 | $315.33K 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $150.73K 10-Q · filed 2020-05-07 | ||||
| 2018-09-30 | $29.38K 10-Q · filed 2019-11-12 | $55.74K derived: sum of 2 quarters · filed 2019-11-12 | $81.90K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $26.36K 10-Q · filed 2019-08-08 | $52.51K 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $26.15K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |